Ocrevus Zunovo (Subcutaneous Ocrelizumab) Safety Profile
The subcutaneous formulation of ocrelizumab (Ocrevus Zunovo) has a distinct safety profile characterized primarily by injection site reactions occurring in approximately 49% of patients, with the majority being mild to moderate local reactions (erythema, pain, swelling, pruritus) that resolve within 3-4 days, representing a shift from the infusion-related reactions seen with IV formulations. 1
Primary Adverse Effects
Injection Reactions (Most Common)
- Incidence: 49% after first injection 1
- Local reactions (47%): injection site erythema, pain, swelling, pruritus
- Systemic reactions (11%): headache, nausea
- Timing: 83% occur within 24 hours post-injection (not during injection itself)
- Severity: All mild (73%) or moderate (27%) - no severe reactions reported
- Duration: Median 3-3.5 days
- Management: 26% required symptomatic treatment; all patients recovered
- Subsequent doses: Frequency decreases (31-43% local, 3-7% systemic for injections 2-4) 1
Infections (Shared with IV Formulation)
The infection risk profile mirrors IV ocrelizumab:
Common infections (≥10%):
- Upper respiratory tract infections (most common)
- Skin infections
- Lower respiratory tract infections 1
Serious infections requiring monitoring:
- Herpes virus infections (including herpes zoster)
- Progressive multifocal leukoencephalopathy (PML) - postmarketing reports
- Serious herpes infections
- Babesiosis 1
Recent pharmacovigilance data identifies additional infection signals including enteroviral encephalitis/meningitis, neuroborreliosis, and COVID-19 complications 2.
Laboratory Abnormalities
Immunoglobulin Depletion
- IgM: Most affected - 15.5-16.5% below lower limit of normal (LLN) at 96-120 weeks
- IgG: 1.1-1.5% below LLN at 96-120 weeks
- Critical finding: Decreased IgG levels associated with increased serious infection rates 1
- Duration of risk: Up to 7 years of exposure data shows persistent association
Neutropenia
- 13% develop decreased neutrophil counts (vs 10% placebo)
- Majority remain >1.0 × 10⁹/L
- 1% drop below 1.0 × 10⁹/L (not associated with infections in trials) 1
Postmarketing Safety Signals
Beyond the label, real-world data reveals:
- Immune-mediated colitis
- Pyoderma gangrenosum
- Alopecia, insomnia, weight gain, sepsis (newly identified signals) 3
- Malignancy concerns: Breast cancer reported in trials 1
Critical Safety Considerations
Pre-Treatment Screening Required
Based on consensus recommendations 4:
- Tuberculosis screening (QuantiFERON or PPD)
- Hepatitis B and C serology
- HIV testing
- Varicella-zoster virus immunity
- Baseline immunoglobulin levels
- Complete blood count with differential
Contraindications and Precautions
- Active infections: Defer treatment until resolved
- Hepatitis B: Risk of reactivation - requires monitoring
- Live vaccines: Contraindicated during treatment and until B-cell recovery
- Pregnancy: Limited safety data 1
Drug Interactions
Avoid concomitant use with:
- Immunosuppressive therapies (additive immunosuppression risk)
- Drugs with prolonged immune effects (daclizumab, fingolimod, natalizumab, teriflunomide, mitoxantrone) - consider washout periods 1
Monitoring Algorithm
Baseline: CBC, immunoglobulins (IgG, IgA, IgM), infection screening panel
During treatment:
- Monitor for injection reactions (first 24 hours post-injection most critical)
- Check immunoglobulin levels every 6 months
- If IgG falls below LLN: increase infection surveillance, consider IVIG replacement if recurrent serious infections
- Monitor for signs of PML (new neurological symptoms, cognitive changes)
- Screen for infections before each dose
Post-injection management:
- Observe for delayed reactions (up to 24 hours)
- Symptomatic treatment for local reactions (ice, antihistamines, NSAIDs)
- Subsequent injections typically better tolerated
Key Clinical Pitfalls
- Underestimating delayed injection reactions: Unlike IV infusion reactions that occur during administration, SC reactions predominantly occur post-injection
- Ignoring IgG decline: The association between low IgG and serious infections is established - requires proactive monitoring
- Inadequate infection screening: Pre-treatment screening is essential given the broad infection risk profile
- Live vaccine administration: Must be avoided; complete vaccination before starting therapy
The subcutaneous formulation offers convenience with a manageable safety profile, but requires the same vigilant infection monitoring as IV ocrelizumab, with additional attention to injection site management 1, 5.